$2.22
3.48% today
Nasdaq, Feb 28, 04:47 pm CET
ISIN
US36254L2097
Symbol
GTBP
Sector
Industry

GT Biopharma Inc Stock price

$2.30
+0.26 12.75% 1M
+0.06 2.77% 6M
-0.75 24.59% YTD
-1.83 44.31% 1Y
-93.10 97.59% 3Y
-47.68 95.40% 5Y
-897,342.70 100.00% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.06 2.54%
ISIN
US36254L2097
Symbol
GTBP
Sector
Industry

Key metrics

Market capitalization $5.14m
Enterprise Value $1.10m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-14.36m
Free Cash Flow (TTM) Free Cash Flow $-12.90m
Cash position $4.04m
EPS (TTM) EPS $-7.02
Short interest 0.81%
Show more

Is GT Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

GT Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast GT Biopharma Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast GT Biopharma Inc:

Buy
100%

Financial data from GT Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.57 8.57
21% 21%
-
- Research and Development Expense 5.80 5.80
10% 10%
-
-14 -14
6% 6%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -14 -14
6% 6%
-
Net Profit -13 -13
73% 73%
-

In millions USD.

Don't miss a Thing! We will send you all news about GT Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

GT Biopharma Inc Stock News

Neutral
GlobeNewsWire
3 days ago
SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (“NK”) cell engager platform, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to...
Neutral
GlobeNewsWire
4 months ago
SAN FRANCISCO, CALIFORNIA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced third quarter 2024 financial results for the period ended September 30, 2024.
Neutral
GlobeNewsWire
5 months ago
SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced that Dr. Jeffrey Miller, MD1, from the University of Minnesota Medical School2 and GT Biopharma'...
More GT Biopharma Inc News

Company Profile

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product GTB-3550 is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Beverly Hills, CA.

Head office United States
CEO Michael Breen
Employees 1
Founded 1965
Website www.gtbiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today